

United Kingdom: Teva UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG, Court of Appeal of England and Wales, Civil Division, A3 2016 0271, 16 December 2016

Kluwer Patent Blog

June 2, 2018

Adrian Chew (Bristows)

*Please refer to this post as: Adrian Chew, 'United Kingdom: Teva UK Ltd v
Boehringer Ingelheim Pharma GmbH & Co KG, Court of Appeal of England and
Wales, Civil Division, A3 2016 0271, 16 December 2016', Kluwer Patent Blog, June
2 2018,
[http://patentblog.kluweriplaw.com/2018/06/02/united-kingdom-teva-uk-ltd-v-boehri-
nger-ingelheim-pharma-gmbh-co-kg-court-of-appeal-of-england-and-wales-civil-
division-a3-2016-0271-16-december-2016-2/](http://patentblog.kluweriplaw.com/2018/06/02/united-kingdom-teva-uk-ltd-v-boehri-
nger-ingelheim-pharma-gmbh-co-kg-court-of-appeal-of-england-and-wales-civil-
division-a3-2016-0271-16-december-2016-2/)*

The Court of Appeal dismissed Boehringer Ingelheim's application for permission to appeal the first instance Patents Court decision that EP (UK) 1,379,220 lacked inventive step. The Court of Appeal also considered and overturned the existing judicial guidance on granting permission to appeal in patent matters.

A full summary of this case has been published on [Kluwer IP Law](#)